Skip to main content
AAN.com
Articles
March 1, 2001

Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability

March 1, 2001 issue
56 (suppl_1) S20-S28

Abstract

Article abstract The MIDAS Questionnaire was developed to assess headache-related disability with the aim of improving migraine care. Headache sufferers answer five questions, scoring the number of days, in the past 3 months, of activity limitations due to migraine. The internal consistency, test–retest reliability, and validity (accuracy) of the questionnaire were assessed in separate population-based studies of migraine sufferers. In addition, the face validity, ease of use, and clinical utility of the questionnaire were evaluated in a group of 49 physicians who independently rated disease severity and need for care in a diverse sample of migraine case histories. The test–retest Pearson correlation coefficient for the total MIDAS score was approximately 0.8. The MIDAS score was valid when compared with a reference diary-based measure of disability; the overall correlation between MIDAS and the diary-based measure was 0.63. The MIDAS score was also correlated with physicians’ assessments of need for medical care (r = 0.69). From studies completed to date, the MIDAS Questionnaire has been shown to be internally consistent, highly reliable, valid, and correlates with physicians’ clinical judgment. These features support its suitability for use in clinical practice. Use of the MIDAS Questionnaire may improve physician–patient communication about headache-related disability and may favorably influence health-care delivery for migraine patients.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Lipton RB, Amatniek JC, Ferrari MD, et al. Migraine: identifying and removing barriers to care. Neurology . 1994; 44 (suppl 4): 63–68.
2.
Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology . 1994; 44 (suppl 4): 24–39.
3.
Lipton RB, Goadsby PJ, Sawyer JPC, et al. Migraine: diagnosis and assessment of disability. Rev Contemp Pharmacother . 2000; 11: 63–73.
4.
Dahlöf C. Assessment of health-related quality of life in migraine. Cephalalgia . 1993; 13: 233–237.
5.
Jacobson GP, Ramadan NM, Aggarwal SK, et al. The Henry Ford Hospital Headache Disability Inventory. Neurology . 1994; 44: 837–842.
6.
Babiak LM, Miller DW, MacMillan JH, et al. Migraine-specific quality of life: a comparison of US and Canadian results. Qual Life Res . 1994; 3: 58.Abstract.
7.
Richard A, Henry P, Chezot G, et al. Quality of life and migraine, validation of the QVM questionnaire in hospital consultation and in general medicine [in French]. Therapie . 1993; 48: 89–96.
8.
Solomon GD, Skobieranda FG, Graff LA. Quality of life and well-being of headache patients: measurement by the Medical Outcomes Study Instrument. Headache . 1993; 33: 351–358.
9.
Osterhaus JT, Townsend RJ, Gandek B, et al. Measuring the functional status and well-being of patients with migraine headache. Headache . 1994; 34: 337–343.
10.
Wagner TH, Patrick DL, Galer BS, et al. A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL. Headache . 1996; 36: 484–492.
11.
National Academy of Sciences/Institute of Medicine (NAS/IOM). Disability in America: toward a national agenda for prevention. Washington, DC: NAS Press, 1991.
12.
Janca A, Prilipko, Costa E, Silva JA. The World Health Organization’s global initiative on neurology and public health. J Neurol Sci . 1997; 145: 1–2.
13.
Murray CJL, Lopez AD. The global burden of disease. Geneva: World Health Organization, 1996.
14.
Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet . 1997; 349: 1269–1276.
15.
Murray CJL, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global Burden of Disease Study. Lancet . 1997; 349: 1347–1352.
16.
Stewart WF, Lipton RB, Simon D, et al. Reliability of an illness severity measure for headache in a population sample of migraine sufferers. Cephalalgia . 1998; 18: 44–51.
17.
Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med . 1997; 39: 320–327.
18.
Von Korff MR, Stewart WF, Simon DJ, et al. Migraine and reduced work performance—a population-based diary study. Neurology . 1998; 50: 1741–1745.
19.
Rasmussen B, Jensen R, Olesen J. Impact of headache on sickness absence and utilisation of medical services: a Danish population study. J Epidemiol Community Health . 1992; 46: 443–446.
20.
de Lissovoy G, Lazarus SS. The economic cost of migraine. Present state of knowledge. Neurology . 1994; 44 (suppl 4): 56–62.
21.
Slater ND, Lipton RB, Stewart WF, et al. Doctor–patient communication about migraine disability. Neurology . 1999; 52 (suppl 2): A209.Abstract.
22.
Lipton RB, Stewart WF, MacGregor A, et al. Communication of migraine disability between physicians and patients. Cephalalgia . 1999; 19: 337.Abstract.
23.
Von Korff M, Ormel J, Keefe FJ, et al. Grading the severity of chronic pain. Pain . 1992; 50: 133–149.
24.
Stewart WF, Lipton RB, Simon D, et al. Validity of an illness severity measure for headache in a population sample of migraine sufferers. Pain . 1999; 79: 291–301.
25.
Stewart WF, Lipton RB, Kolodner K, et al. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia . 1999; 19: 107–114.
26.
Stewart WF, Lipton RB, Sawyer J. An international study to assess the reliability of the Migraine Disability Assessment (MIDAS) score. Neurology . 1999; 52: 988–994.
27.
Stewart WF, Lipton RB, Kolodner KB, et al. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain . 2000; 88: 41–52.
28.
Scher AI, Stewart WF, Lipton RB. Migraine and headache: a meta-analytic approach. In: Crombie IK, ed. Epidemiology of pain. Seattle: IASP Press, 1999: 159–170.
29.
Lipton RB, Stewart WF, Liberman J, et al. Validation of a computer assisted telephone interview for migraine (CATI-M): results of independent validation studies in the US and the UK. Headache . 2000; 40: 417.Abstract.
30.
Lipton RB, Stewart WF, Sawyer J, et al. Clinical utility of a new instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) Questionnaire. Headache. Submitted.
31.
Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol . 1991; 31: 295–299.

Information & Authors

Information

Published In

Neurology®
Volume 56Number suppl_1March 1, 2001
Pages: S20-S28
PubMed: 11294956

Publication History

Published online: March 1, 2001
Published in print: March 1, 2001

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

Walter F. Stewart, MPH, PhD
From the Johns Hopkins School of Public Health, Baltimore, MD and Innovative Medical Research, Inc., Hunt Valley, MD (Dr. Stewart); the Albert Einstein College of Medicine, Bronx, NY and Innovative Medical Research, Inc., Stamford, CT (Dr. Lipton); the Kings Headache Service, Kings College Hospital, London, UK (Dr. Dowson); and Willaston, Cheshire, UK (Dr. Sawyer).
Richard B. Lipton, MD
From the Johns Hopkins School of Public Health, Baltimore, MD and Innovative Medical Research, Inc., Hunt Valley, MD (Dr. Stewart); the Albert Einstein College of Medicine, Bronx, NY and Innovative Medical Research, Inc., Stamford, CT (Dr. Lipton); the Kings Headache Service, Kings College Hospital, London, UK (Dr. Dowson); and Willaston, Cheshire, UK (Dr. Sawyer).
Andrew J. Dowson, MB
From the Johns Hopkins School of Public Health, Baltimore, MD and Innovative Medical Research, Inc., Hunt Valley, MD (Dr. Stewart); the Albert Einstein College of Medicine, Bronx, NY and Innovative Medical Research, Inc., Stamford, CT (Dr. Lipton); the Kings Headache Service, Kings College Hospital, London, UK (Dr. Dowson); and Willaston, Cheshire, UK (Dr. Sawyer).
James Sawyer, MB
From the Johns Hopkins School of Public Health, Baltimore, MD and Innovative Medical Research, Inc., Hunt Valley, MD (Dr. Stewart); the Albert Einstein College of Medicine, Bronx, NY and Innovative Medical Research, Inc., Stamford, CT (Dr. Lipton); the Kings Headache Service, Kings College Hospital, London, UK (Dr. Dowson); and Willaston, Cheshire, UK (Dr. Sawyer).

Notes

Address correspondence and reprint requests to Dr. Walter Stewart, Innovative Medical Research, Inc., 1200 High Ridge Road, Stamford, CT 06905. e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Neuropsychological Function in Migraine Headaches, Neurology, 102, 4, (2024)./doi/10.1212/WNL.0000000000208109
    Abstract
  2. Migraine-Related Stigma and Its Relationship to Disability, Interictal Burden, and Quality of Life, Neurology, 102, 3, (2024)./doi/10.1212/WNL.0000000000208074
    Abstract
  3. Evaluation of forward head posture and thoracic kyphosis in migraine, Journal of Clinical Neuroscience, 119, (17-21), (2024).https://doi.org/10.1016/j.jocn.2023.11.018
    Crossref
  4. Epidemiology of Migraines in Iraqi Females: Emphasis on Dietary Influence, Cureus, (2023).https://doi.org/10.7759/cureus.44080
    Crossref
  5. Revisiting Migraine: The Evolving Pathophysiology and the Expanding Management Armamentarium, Cureus, (2023).https://doi.org/10.7759/cureus.34553
    Crossref
  6. Decreased serum magnesium levels patients with migraine: a case control study, International Archives of Medical Research, 15, 1, (26-32), (2023).https://doi.org/10.56484/iamr.1217558
    Crossref
  7. The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody, Annals of Clinical and Experimental Neurology, 17, 2, (22-27), (2023).https://doi.org/10.54101/ACEN.2023.2.3
    Crossref
  8. Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial, Journal of Clinical Neurology, 19, 5, (483), (2023).https://doi.org/10.3988/jcn.2022.0180
    Crossref
  9. The Effect of OnabotulinumtoxinA on Headache Intensity and Number of Monthly Headache Days in Individuals with Chronic Migraine with Different Levels of Neck Disability, Toxins, 15, 12, (685), (2023).https://doi.org/10.3390/toxins15120685
    Crossref
  10. A Single-Group Study on the Effect of OnabotulinumtoxinA in Patients with Chronic Migraine Associated with Medication Overuse Headache: Pain Catastrophizing Plays a Role, Toxins, 15, 2, (86), (2023).https://doi.org/10.3390/toxins15020086
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share